» Articles » PMID: 10873591

Expression of Guanylin is Downregulated in Mouse and Human Intestinal Adenomas

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2000 Jun 30
PMID 10873591
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Guanylin is a pro-secretory hormone that is expressed in intestinal epithelia. Previously, we mapped the guanylin gene to mouse and human chromosomal regions containing multiple intestinal tumor-modifying loci. Here, we investigate whether guanylin expression is downregulated in precancerous human and mouse intestinal adenomas and whether diminished guanylin expression increases adenoma susceptibility in an animal model of intestinal cancer, the multiple intestinal neoplasia (Min) mouse. In situ hybridization analysis indicated diminished guanylin expression in both mouse and human adenomas. Northern analysis of mouse intestinal tissues showed strain-specific levels of guanylin expression but no correlation with the resistance or susceptibility of each strain to adenoma formation. Similarly, cDNA sequence analysis indicated no inactivating mutations or polymorphisms common to either the high or low adenoma-risk groups. Nonetheless, we have shown that significant loss of guanylin RNA in adenomas of mouse and human is a marker of intestinal epithelial cell transformation.

Citing Articles

Type-2 cGMP-dependent protein kinase suppresses proliferation and carcinogenesis in the colon epithelium.

Islam B, Sharman S, Hou Y, Wang R, Ashby J, Li H Carcinogenesis. 2022; 43(6):584-593.

PMID: 35188962 PMC: 9234760. DOI: 10.1093/carcin/bgac022.


Inhibition of Colon Cancer Cell Growth by Phosphodiesterase Inhibitors Is Independent of cGMP Signaling.

Hou Y, Wren A, Mylarapu N, Browning K, Islam B, Wang R J Pharmacol Exp Ther. 2022; 381(1):42-53.

PMID: 35110391 PMC: 8998686. DOI: 10.1124/jpet.121.001075.


A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer.

Rappaport J, Entezari A, Caspi A, Caksa S, Jhaveri A, Stanek T Cell Mol Gastroenterol Hepatol. 2021; 13(4):1276-1296.

PMID: 34954189 PMC: 9073733. DOI: 10.1016/j.jcmgh.2021.12.014.


Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.

Weinberg D, Foster N, DellaZanna G, McMurray R, Kraft W, Pallotto A Cancer Biol Ther. 2021; 22(10-12):544-553.

PMID: 34632925 PMC: 8726613. DOI: 10.1080/15384047.2021.1967036.


Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.

Entezari A, Snook A, Waldman S Expert Opin Ther Targets. 2021; 25(5):335-346.

PMID: 34056991 PMC: 8363580. DOI: 10.1080/14728222.2021.1937124.